BR9510554A - Uso de moléculas de ligação de mch-ii e/ou moléculas de imitação para a prevenção e/ou tratamento de doenças inflamatórias - Google Patents

Uso de moléculas de ligação de mch-ii e/ou moléculas de imitação para a prevenção e/ou tratamento de doenças inflamatórias

Info

Publication number
BR9510554A
BR9510554A BR9510554A BR9510554A BR9510554A BR 9510554 A BR9510554 A BR 9510554A BR 9510554 A BR9510554 A BR 9510554A BR 9510554 A BR9510554 A BR 9510554A BR 9510554 A BR9510554 A BR 9510554A
Authority
BR
Brazil
Prior art keywords
molecules
mch
imitation
prevention
treatment
Prior art date
Application number
BR9510554A
Other languages
English (en)
Portuguese (pt)
Inventor
Roger Pascal Lauener
Original Assignee
Om Lab Sa
Deutsche Om Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh filed Critical Om Lab Sa
Publication of BR9510554A publication Critical patent/BR9510554A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
BR9510554A 1994-12-23 1995-12-27 Uso de moléculas de ligação de mch-ii e/ou moléculas de imitação para a prevenção e/ou tratamento de doenças inflamatórias BR9510554A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
PCT/EP1995/005164 WO1996020215A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
BR9510554A true BR9510554A (pt) 1999-06-29

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9510554A BR9510554A (pt) 1994-12-23 1995-12-27 Uso de moléculas de ligação de mch-ii e/ou moléculas de imitação para a prevenção e/ou tratamento de doenças inflamatórias

Country Status (11)

Country Link
EP (1) EP0800534A2 (cs)
JP (1) JPH10511652A (cs)
CN (1) CN1171117A (cs)
AU (1) AU4347696A (cs)
BR (1) BR9510554A (cs)
CA (1) CA2208233A1 (cs)
CZ (1) CZ186897A3 (cs)
HU (1) HUT77468A (cs)
PL (1) PL320922A1 (cs)
SK (1) SK80697A3 (cs)
WO (1) WO1996020215A2 (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6015884A (en) 1996-03-28 2000-01-18 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) * 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
KR20040030786A (ko) 2001-07-02 2004-04-09 아임스코 리미티드 폴리클론항체 항-hiv 산양 혈청의 치료제로의 용도
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
CA2473754C (en) * 2002-01-28 2012-04-10 Aimsco Limited Treatment of ms with goat serum
ES2232273B1 (es) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos Nuevas aplicaciones terapeuticas de la glucoproteina cd14s.
CA2524534C (en) * 2003-05-15 2012-12-11 Sek Chung Fung Methods and compositions for the prevention and treatment of sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (en) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
EP0204522A3 (en) * 1985-05-30 1987-09-16 Genetic Systems Corporation Monoclonal antibody panel for histocompatibility typing
JPS63275526A (ja) * 1987-05-03 1988-11-14 Hiroshi Okajima Ｈｉｖウイルス中和抗体
FR2658197B1 (fr) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993010220A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
CA2133758A1 (en) * 1992-04-06 1993-10-14 Sanna M. Goyert A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
DE69332268T2 (de) * 1992-10-15 2003-08-14 Toray Industries Verfahren zur herstellung von rekombinant mhcii protein in mikroorganismen
WO1994028025A1 (en) * 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
AU4347696A (en) 1996-07-19
WO1996020215A2 (en) 1996-07-04
HUT77468A (hu) 1998-05-28
CN1171117A (zh) 1998-01-21
PL320922A1 (en) 1997-11-10
CZ186897A3 (cs) 1998-03-18
SK80697A3 (en) 1997-12-10
JPH10511652A (ja) 1998-11-10
WO1996020215A3 (en) 1996-10-10
EP0800534A2 (en) 1997-10-15
CA2208233A1 (en) 1996-07-04

Similar Documents

Publication Publication Date Title
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
BR9504072A (pt) Composiçao farmacêutica métodos para o tratamento de hipercolesterolemia de aterosclerose e kit
FI951801A (fi) CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
BR9711530A (pt) Combina-Æo de terapia para tratamento de psicoses
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
PT966436E (pt) Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
IS4481A (is) Díhýdrópyramídín og notkun þeirra
BR9505368A (pt) Composição cosmética ou dermatogógico água-em-óleo
BR9504385A (pt) Composto composiçao farmaceutica metodos para a inibiçao de ligaçao e para o tratamento de dersordens inflamatorias
PT752870E (pt) Utilizacao de mycobacterium para o tratamento de tumores
BR9510554A (pt) Uso de moléculas de ligação de mch-ii e/ou moléculas de imitação para a prevenção e/ou tratamento de doenças inflamatórias
PT777457E (pt) A utilizacao de triacetato de glicerilo para o tratamento de onicomicoses
PT928193E (pt) Utilizacao de 1-hidroxi-2-piridonas para o tratamento de infeccoes da pele
DE59707096D1 (de) Haarbehandlungsmittel zur Festigung der Haare
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
NO965247D0 (no) Anvendelse av kryssbundet hemoglobin ved behandling av subarakuoidalblödning
BR9709636A (pt) Uso de buckminsterfulereno no tratamento de ferimento neurotóxico
BR9608595A (pt) Utilização de n-cicloexil benzamidas para o tratamento de aglições intestinais
BR9606631A (pt) Preparado para o tratamento e condicionamento do cabelo e seu emprego
BR9507732A (pt) Composição farmacêutica para o tratamento de glaucoma
PT804199E (pt) Uso de penciclovir para o tratamento de nevralgias pos-herpeticas
BR9507133A (pt) N-aril e n-alquilsulfonilaminais
AU2520395A (en) Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]